Avacopan Shows Efficacy Signal for Rare Kidney Disease, C3G Avacopan Shows Efficacy Signal for Rare Kidney Disease, C3G

Avacopan, recently FDA approved for ANCA-associated vasculitis, showed significant benefit for reducing disease chronicity in a randomized trial of 52 patients with C3 glomerulopathy.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Nephrology News Source Type: news